Oliver about the aims of Oxford Nanopore and the relation with FEMS: “Our goal at Oxford Nanopore Technologies is to enable the analysis of any living thing, by any person, in any environment. We aim to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. Our novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. These include large scale human genomics, cancer research, microbiology, plant science and environmental research.
FEMS2019 will bring together leading scientists spanning different fields of microbiology. We believe our technology can address the variety of DNA/RNA focused applications within these exciting fields by enabling anyone to have access to real-time, low cost sequencing on our MinION, GridION and PromethION platforms.”
You will be at the exhibition of FEMS2019. About what topics should congress attendees come and meet you?
“About effective ways to explore complete bacterial, fungal and viral genomes with nanopore sequencing. Our technology allows researchers to identify and characterise microbes from environmental or single organism samples, with rapid methods for pathogen detection - whether at the bench or in the field. This can be accompanied, if required, with antimicrobial resistance profiling.”
Which of your products are interesting to the microbiology community?
“A significant advantage of nanopore sequencing is that data is streamed in real-time, allowing for rapid data analysis, which can drastically reduce time to result. With nanopore technology, read length is only limited by the size of the DNA/RNA fragment. Oxford Nanopore’s pocket sized MinION sequencing device allows users to run DNA/RNA sequencing experiments with minimal resource required.”
Oliver Hartwell has been with Oxford Nanopore for over 7 years, initially starting with the company’s sequencing development team. During that time, Oliver worked in a small team whose focus was to develop and launch the MinION sequencer into an early access programme in 2014. Since then, Oliver has progressed through a number of commercial roles in support and sales, and he is now responsible for managing the growing sales team in the Europe North region.